Cilique 250/ 35 microgram tablets *
Pharmacy Only: Prescription

EDM Updated on 01 April 2022

File name

HUG5367 Consilient Cillique A5 RMM v3[1]_1648829345.pdf

Reasons for updating

  • Add New Doc

EDM Updated on 01 April 2022

File name

HUG5367 A4 Cillique RMM Thromboembolism Checklist v7[1]_1648829301.pdf

Reasons for updating

  • Add New Doc

Updated on 23 November 2021

File name

ie-spc-v0014-appr. 19.11.21_1637670057.pdf

Reasons for updating

  • Change to Section 4.8 – Undesirable effects - how to report a side effect

Legal category:Product subject to medical prescription which may be renewed (B)

Updated on 23 November 2021

File name

02_P1371_Appr. 19.11.2021_1637669919.pdf

Reasons for updating

  • Change to section 4 - possible side effects

Updated on 14 September 2021

File name

ie-spc-v0013 appr. 08.09.21_1631626252.pdf

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction

Legal category:Product subject to medical prescription which may be renewed (B)

Updated on 14 September 2021

File name

P1294_Cilique appr. 14.09.21_1631624625.pdf

Reasons for updating

  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 2 - interactions with other medicines, food or drink

Updated on 09 January 2020

File name

P1088 - v007_1578579655.pdf

Reasons for updating

  • Change to section 2 - what you need to know - warnings and precautions

Free text change information supplied by the pharmaceutical company

To include the following contraindication in section 2.1 of our package leaflet: ‘If you have cancer affected by sex hormones – such as some cancers of the breast or womb lining’

Updated on 16 October 2019

File name

common-spc-v005_1571238520.pdf

Reasons for updating

  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.9 - Overdose

Legal category:Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Update of the product information in line with the reference product.

Updated on 16 October 2019

File name

P0889_v005_1571238415.pdf

Reasons for updating

  • Change to Section 1 - what the product is
  • Change to section 2 - what you need to know - contraindications
  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 3 - how to take/use
  • Change to section 4 - possible side effects
  • Change to section 4 - how to report a side effect

Free text change information supplied by the pharmaceutical company

Update of the product information in line with the reference product.

Updated on 11 March 2019

File name

Cilique-common-mockup_1552306928.pdf

Reasons for updating

  • Change to section 2 - what you need to know - warnings and precautions
  • Change to date of revision

Updated on 11 March 2019

File name

Cilique-common-spc-clean-17.12.2018_1552307194.pdf

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may be renewed (B)

Updated on 01 October 2018

File name

2. pil-mock-up_1538388932.pdf

Reasons for updating

  • New PIL for new product

Updated on 01 October 2018

File name

1. common-spc-revised-17.11.2015_1538389083.pdf

Reasons for updating

  • New SPC for new product

Legal category:Product subject to medical prescription which may be renewed (B)